ArticleStem cell reviews and reports2026
8-Me-PIQ Expands Cord Blood CD34
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Umbilical cord blood (UCB) is a clinically validated and readily available source for hematopoietic stem cell transplantation (HSCT). However, its widespread application in adults is constrained by the limited hematopoietic stem cell (HSC) dose per unit, necessitating effective strategies for ex vivo HSC expansion while preserving stemness. We conducted a phenotypic screen using a miniaturized scaffold library to identify novel small molecules capable of expanding human UCB-HSCs. This effort identified 8-methyl-4-((4-isopropylphenyl)amino)-[1,2,4]triazolo[4,3-a]quinoxaline (designated 8-Me-PIQ) as a potent activator of HSC expansion. In serum-free cultures, 8-Me-PIQ significantly increased the frequency and absolute number of phenotypic HSCs (CD34+CD38−CD45RA−CD90+CD49f+). Critically, primary and secondary transplantation in immunodeficient mice demonstrated that 8-Me-PIQ-expanded CD34+ HSC and progenitor cells (HSPCs) retained robust long-term multilineage reconstitution and self-renewal capacity, confirming functional stem cell maintenance. Mechanistically, transcriptomic analysis of 8-Me-PIQ-treated HSPCs revealed significant downregulation of gene signatures associated with oxidative phosphorylation and ribosome biogenesis. Functional assays confirmed a quiescent-like metabolic state, demonstrating reduced mitochondrial mass, decreased mitochondrial reactive oxygen species, and a lower oxygen consumption rate (OCR). We further show that 8-Me-PIQ attenuates ribosome biogenesis through the inhibition of RNA polymerase I transcriptional activity, establishing a direct link between the compound, translational control, and the maintenance of protein homeostasis during ex vivo culture. These findings provide a promising small-molecule candidate for improving UCB transplantation outcomes and offer new insights into the metabolic and translational checkpoints governing HSC stemness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.